CONSORT diagram showing enrollment and follow-up of study subjects.
We further investigated the association of specific anti-cancer therapies with the booster effect. Patients on Bruton’s tyrosine kinase inhibitor (BTKi) therapy (n=12) had a median rise in anti-S antibody of 0 AU/mL (IQR 0–3393 AU/mL) compared to a median rise of 9355 AU/mL (IQR 877.3–34410 AU/mL) in anti-S antibody for patients not on BTKi (p<0.05) (